New combo therapy shows promise for Hard-to-Treat breast cancer
Disease control
Recruiting now
This study tests whether adding tinengotinib to fulvestrant can shrink tumors in people with a common type of advanced breast cancer (HR+/HER2-). About 94 adults whose cancer has returned or spread despite prior treatments will take part. The goal is to find the best dose and see…
Phase: PHASE2 • Sponsor: TransThera Sciences (Nanjing), Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC